Billionaire Stanley Druckenmiller Just Bet Big on This Hot IPO Stock. Is It a Buy?

Stanley Druckenmiller disclosed a 4.26 million-share purchase of StubHub in Q3, a notable concentrated bet as the ticket-resale IPO has slid from a $23.50 debut on Sept. 16 to below $11 by Nov. 19. StubHub’s first post‑IPO results showed GMS up 11% to $2.43 billion (24% ex–Taylor Swift), revenue up 8% to $468.1 million (versus $451.4 million consensus) and adjusted EBITDA up 21% to $67.5 million with margins expanding to 14%, but the stock dropped after management declined to give fourth‑quarter guidance and analysts cut targets. The company also faces material regulatory risk after reports of a potential U.K. ban on above‑face‑value resales and a CMA probe into pricing practices; at roughly $4 billion market cap (~15x run‑rate EBITDA), StubHub will need to reassure investors on growth and regulatory exposure for a recovery to be plausible.

Analysis

Stanley Druckenmiller disclosed a 4.26 million-share purchase of StubHub (STUB) in Q3, a notable concentrated macro bet given his record; the stock debuted at $23.50 on Sept. 16 and slumped to under $11 by Nov. 19, signaling significant post-IPO weakness. StubHub reported its first public-quarter results showing gross merchandise sales (GMS) up 11% to $2.43 billion and revenue up 8% to $468.1 million versus a $451.4 million consensus, while adjusted EBITDA rose 21% to $67.5 million and adjusted EBITDA margin expanded to 14% from 13%. Adjusting for Taylor Swift's Eras Tour, GMS was up 24%, indicating event-driven strength, but shares fell after management declined to provide fourth-quarter guidance and analysts trimmed price targets. Regulatory and competitive risk are immediate headwinds: the Financial Times reported the U.K. may ban above-face-value ticket resales and the U.K. Competition and Markets Authority has opened a probe into drip pricing and pressure-selling practices; at roughly a $4 billion market cap (~15x run-rate EBITDA) the valuation looks reasonable only if growth and regulatory exposure are clarified and contained.

Key Decisions for Investors

• Consider a small, opportunistic position to mirror Druckenmiller's conviction only if you accept concentrated, event-driven upside and the stated regulatory risks
• Delay larger allocations until management provides explicit fourth-quarter guidance and until there is clarity on the U.K. legislative proposal and the CMA investigation
• Use operating metrics — GMS ex-Taylor Swift, sequential revenue growth, and adjusted EBITDA margin expansion — as primary triggers to add to the position
• If already long, consider partial trimming or hedging to limit exposure to further regulatory shocks and continued post-IPO volatility